3 1998, 3 1, chimeric protein containing intramolecular chaperone-like sequence and its application technology in insulin production applied for international patent. On March 3rd,1998, 10 was approved by the state medical and drug administration, and the new drug certificate and production number of recombinant human insulin-ganshulin were obtained.
1998 65438+February 1 1 The press conference on the successful development of recombinant human insulin in China was held in the press room of Xinhua News Agency.
200 1 Hire Dr. Li to establish Dongbao international market operation platform in Shanghai.
From June 65438 to June 2002, the national high-tech industrialization demonstration project of recombinant human insulin was laid.
In 2003, a series of products such as Ganshulin refill and Dongbao pen were launched.
At the end of 2003, we hired a group of professional managers with rich experience in insulin sales, led by Li Cong, and established the domestic Ganshulin Marketing Center.
/10 2008 On June 23rd, 2008, after six years' construction, the second phase expansion project of recombinant human insulin freeze-dried powder production line with an annual output of 3,000 kg was successfully put into trial operation and passed the national GMP certification. This indicates that tonghua dongbao has become the largest recombinant human insulin production base in Asia and one of the three largest recombinant human insulin production bases in the world.
In the first half of 2009, the expansion project of 70 million injections with an investment of 200 million yuan was completed, and it has entered the stage of equipment installation, debugging and GMP certification.
20 10 1 1 launched the only insulin injection pen in the world "ganshulin pen ganshulin pen".
20 10- 12 Beijing dongbao pharmaceutical co., ltd. invested capital to build a new insulin preparation construction project that meets the requirements of the FDA of the United States and the CGMP of the European union, with an annual production scale of 65438+200 million tablets.
201165438+1October 24th, "listing of Gansu North China" was held in Beijing International Hotel Conference Center, and the meeting was presided over by Professor Mu, director of endocrinology department of PLA General Hospital. Professor Guo Xiaohui from the Department of Endocrinology of the First Hospital of Peking University gave a wonderful speech on "Key Factors Affecting the Treatment of Diabetic Patients", and Simon Michel, manager of Swiss YPSOMED Company, introduced the product features and related information of "Ganshulin Basin". It is agreed that the newly listed "Ganshulin Pen" is the most convenient insulin injection pen among all kinds of insulin injection pens.
20 1 1 On May 6th, 2008, the kick-off meeting of "Dandelion Action-Training Program for Primary Diabetes Doctors in China" was held in Beijing Convention Center. Xie Qilin, director of the member department of China Medical Doctor Association, attended the kick-off meeting and delivered a speech. Professor Guo Xiaohui, director of the Expert Committee, pointed out at the meeting: "The prevention and treatment of diabetes is an important task for endocrinologists all over the country. The primary doctor training program is to strengthen the diagnosis and treatment norms of primary doctors and better prevent and control diabetes. " The training program will set up training bases for primary diabetes doctors in 26 provinces, autonomous regions and municipalities directly under the Central Government. The event was hosted by the Endocrine and Metabolic Physician Branch of the Chinese Medical Association and co-organized by tonghua dongbao Pharmaceutical Co., Ltd. ..
On the afternoon of 2011July 13, Ms. Ann Kline, CEO of International Diabetes Federation, and her party visited Dongbao Group. Li Yikui, Chairman of Dongbao Group, and Leng Chunsheng, Deputy General Manager, warmly received Ms. An and her party. Ms. An and her party came to Dongbao Group, mainly to inspect the Ganshulin insulin production base on the spot, get a comprehensive understanding of Ganshulin insulin production line and products, and plan to recommend tonghua dongbao as the insulin supplier of the World Health Organization.
On 20 10/1/June 16, the Diabetes Branch of Chinese Medical Association held a press conference and lecturer training meeting of the 20th edition of the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China, announcing that the lecturer training meeting in Northeast China will be held soon. At the same time, instructor training sessions in six sub-regions (South China, East China, Northwest China, Southwest China, North China and Northeast China) and new tour guide training activities in 100 small and medium-sized cities will be launched one after another. After expert evaluation, Gansulin insulin produced by tonghua dongbao Pharmaceutical Co., Ltd., as the only China insulin brand, was selected as the 20 10 version of China's guidelines for the prevention and treatment of type 2 diabetes.
201165438+February 4-8, 2 1 World Diabetes Congress was held in Dubai, United Arab Emirates, jointly organized by the NGO International Diabetes Federation (IDF) and the World Health Organization (WHO). As the first manufacturer of diabetes drugs in China, tonghua dongbao Pharmaceutical Co., Ltd. participated in IDF annual meeting, which caused great repercussions. IDF officials attach great importance to tonghua dongbao's participation in this exhibition. Ms. An, CEO of IDF, came to tonghua dongbao Ganshulin booth twice and met with Mr. Li Cong, General Manager of tonghua dongbao, and Mr. Leng Chunsheng, Vice President, and made it clear that she hoped tonghua dongbao would become its global partner. In this annual meeting, Professor Ji Linong was elected as the new vice chairman of IDF with the highest number of votes, becoming the first vice chairman of IDF in China.
We are on our way. .......